Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery

Stefan Huttenlocher, Lena Sehmisch, Steven E. Schild, Oliver Blank, Dagmar Hornung, Dirk Rades

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Background/Aim: To develop a tool for estimating the risk of developing new cerebral lesions in 69 melanoma patients receiving radiosurgery for 1-3 cerebral metastases. Patients and Methods: Ten factors were investigated: lactate dehydrogenase (LDH), radiosurgery dose, age, gender, performance status, maximum diameter, location and number of cerebral lesions, extra-cranial spread, time between melanoma diagnosis and radiosurgery. Two factors, number of lesions and extra-cranial spread, were included in the tool. Scoring points were achieved by dividing the 6-month rate of freedom from new cerebral lesions by 10. Results: Sum scores were 9, 11, 12 or 14 points. Six-month rates of freedom from new brain metastases were 28%, 63%, 59% and 92% (p=0.002). Three prognostic groups were designed: A (9 points), B (11-12 points) and C (14 points). Freedom from new cerebral lesion rates were 28%, 60% and 92% (p<0.001). Conclusion: Group A and B patients should be considered for additional whole-brain radiotherapy (WBRT).

Original languageEnglish (US)
Pages (from-to)5589-5592
Number of pages4
JournalAnticancer research
Volume34
Issue number10
StatePublished - Oct 1 2014

    Fingerprint

Keywords

  • Melanoma
  • New brain metastases
  • Predictive score
  • Radiosurgery
  • Whole-brain irradiation.

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Huttenlocher, S., Sehmisch, L., Schild, S. E., Blank, O., Hornung, D., & Rades, D. (2014). Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery. Anticancer research, 34(10), 5589-5592.